Guerbet Launches Expanded Portfolio of Microcatheters and Guidewires for Interventional Imaging and Embolization

March 7, 2022—Guerbet announced it will more than double its line of microcatheters and launch a new line of guidewires, resulting in a broad range of interventional imaging and embolization solutions available.

According to Guerbet, the France-based company obtained its original offering of 18 references of SeQure and DraKon microcatheters as part of their acquisition of Accurate Medical Therapeutics, which was announced in January 2018. The SeQure and DraKon microcatheters received FDA clearance on January 26, 2018. In April 2018, the company announced European CE Mark approval of the devices in April 2019.

Guerbet now expands the portfolio, adding 20 versions for a total of 38, and launching a new line of Axessio guidewires with two diameters. A limited market evaluation began in the United States during the fourth quarter of 2021. A commercial launch will begin in Q2 2022 in select markets.

Guerbet is offering a Digital Launch Event to introduce the line extension on March 12th, 2022. Interested parties can find information, register for the event, and enjoy replays, peer learning, and on-demand content at https://launchevent.guerbet.com.

In the press release, the company advised that both the SeQure and DraKon technologies offer interventional radiologists optimized navigation capabilities to enable access to difficult anatomies and reach farther. Additionally, the SeQure reflux control microcatheter enables a fluid barrier technology for flow directed embolization. The new models are designed to deliver more targeted treatment and use a wider range of beads, from extra small to large, stated Guerbet.